These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 18452849)
1. Adverse prognosis of bulky disease in good-risk DLBCL. Ribera JM Lancet Oncol; 2008 May; 9(5):406-7. PubMed ID: 18452849 [No Abstract] [Full Text] [Related]
2. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E; Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558 [TBL] [Abstract][Full Text] [Related]
3. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N; Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214 [TBL] [Abstract][Full Text] [Related]
4. Radiation therapy after R-CHOP for diffuse large B-cell lymphoma: the gain remains. Yahalom J J Clin Oncol; 2010 Sep; 28(27):4105-7. PubMed ID: 20713874 [No Abstract] [Full Text] [Related]
5. Prognostic factors of primary gastric diffuse large B cell lymphoma: a retrospective study of 75 cases in China. Wu YX; Liu B; Chen L; Li JH; Chen SQ Ann Hematol; 2013 Jun; 92(6):861-2. PubMed ID: 23238898 [No Abstract] [Full Text] [Related]
6. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy. Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349 [TBL] [Abstract][Full Text] [Related]
7. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Peyrade F; Jardin F; Thieblemont C; Thyss A; Emile JF; Castaigne S; Coiffier B; Haioun C; Bologna S; Fitoussi O; Lepeu G; Fruchart C; Bordessoule D; Blanc M; Delarue R; Janvier M; Salles B; André M; Fournier M; Gaulard P; Tilly H; Lancet Oncol; 2011 May; 12(5):460-8. PubMed ID: 21482186 [TBL] [Abstract][Full Text] [Related]
8. Clinical disparity and favorable prognoses for patients with Waldeyer ring extranodal nasal-type NK/T-cell lymphoma and diffuse large B-cell lymphoma. Wu RY; Li YX; Wang WH; Jin J; Wang SL; Liu YP; Song YW; Fang H; Ren H; Liu QF; Wang ZY; Qi SN; Lu NN; Chen B; Zhang XM; Zhou LQ; Liu XF; Yu ZH Am J Clin Oncol; 2014 Feb; 37(1):41-6. PubMed ID: 22992625 [TBL] [Abstract][Full Text] [Related]
10. Predictors of delay in diagnosis and treatment in diffuse large B-cell lymphoma and impact on survival. Nikonova A; Guirguis HR; Buckstein R; Cheung MC Br J Haematol; 2015 Feb; 168(4):492-500. PubMed ID: 25324181 [TBL] [Abstract][Full Text] [Related]
11. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. Sehn LH; Donaldson J; Chhanabhai M; Fitzgerald C; Gill K; Klasa R; MacPherson N; O'Reilly S; Spinelli JJ; Sutherland J; Wilson KS; Gascoyne RD; Connors JM J Clin Oncol; 2005 Aug; 23(22):5027-33. PubMed ID: 15955905 [TBL] [Abstract][Full Text] [Related]
12. Survival of patients with transformed lymphoma in the rituximab era. Guirguis HR; Cheung MC; Piliotis E; Spaner D; Berinstein NL; Imrie K; Zhang L; Buckstein R Ann Hematol; 2014 Jun; 93(6):1007-14. PubMed ID: 24414374 [TBL] [Abstract][Full Text] [Related]
13. Predictors of local recurrence after rituximab-based chemotherapy alone in stage III and IV diffuse large B-cell lymphoma: guiding decisions for consolidative radiation. Jegadeesh N; Rajpara R; Esiashvili N; Shi Z; Liu Y; Okwan-Duodu D; Flowers CR; Khan MK Int J Radiat Oncol Biol Phys; 2015 May; 92(1):107-12. PubMed ID: 25863758 [TBL] [Abstract][Full Text] [Related]
14. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components. Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758 [TBL] [Abstract][Full Text] [Related]
15. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. Fabbri A; Gozzetti A; Rigacci L Cancer; 2011 Aug; 117(15):3530; author reply 3531. PubMed ID: 21287541 [No Abstract] [Full Text] [Related]
16. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393 [TBL] [Abstract][Full Text] [Related]
17. Randomized clinical trial to assess the efficacy of radiotherapy in primary mediastinal large B-lymphoma. Avilés A; Neri N; Fernández R; Huerta-Guzmán J; Nambo MJ Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1227-31. PubMed ID: 22172907 [TBL] [Abstract][Full Text] [Related]
18. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967 [TBL] [Abstract][Full Text] [Related]
19. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722 [TBL] [Abstract][Full Text] [Related]
20. Serum albumin as a stable predictor of prognosis during initial treatment in patients with diffuse large B cell lymphoma. Eatrides J; Thompson Z; Lee JH; Bello C; Dalia S Ann Hematol; 2015 Feb; 94(2):357-8. PubMed ID: 25034876 [No Abstract] [Full Text] [Related] [Next] [New Search]